Naldemedine

BreastfeedingPediatric

FDA APPROVAL DATE: 03/23/2017

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Amiodarone, Aprepitant, Atazanavir, Captopril, Carbamazepine, Clarithromycin, Cyclosporine, Diltiazem, Erythromycin, Fluconazole, Itraconazole, Ketoconazole, Moderate or strong CYP3A inhibitors, Other opioid antagonists, P-gp inhibitors, Phenytoin, Quercetin, Quinidine, Rifampin, Ritonavir, Saquinavir, St John's Wort, Strong CYP3A inducers, Verapamil

PREGNANCY CATEGORY: N/A
Potential for opioid withdrawal in fetus

Contra-indicated in patients with known or suspected gastrointestinal obstruction.

Opioid withdrawal symptoms have occurred in patients treated with naldemedine.

Our database has 12 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
GASTROINTESTINAL/HEPATIC.
RESPIRATORY.
OTHER.


Page last updated 08/01/2022

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top